PR90197

PORTSMOUTH, N.H., June 21, 2021 /PRNewswire=KYODO JBN/--

Epredia, a global leader in precision cancer diagnostics, and Aiforia, a

medical software company providing Artificial Intelligence (AI) based solutions

for image analysis in pathology, have announced today that they have entered

into a commercial distribution agreement for Aiforia's comprehensive portfolio

of workflow enhancing solutions which enable pathologists to harness the power

of deep learning AI for image analysis.

Photo - https://mma.prnewswire.com/media/1537009/Clinical_Ki67_IA.jpg

Logo - https://mma.prnewswire.com/media/1458465/Epredia_Logo.jpg

Under the terms of this agreement, Epredia has been appointed as a global

distribution partner for Aiforia's portfolio of preclinical and clinical

pathology tools, including segment exclusivity for distribution in Japan,

Germany, UK, Italy, Spain, Sweden, Norway, Denmark, Iceland, France and the

USA. From Summer 2021, Epredia will begin to commercialize the Aiforia

portfolio of AI solutions. These solutions will be available as part of

Epredia's comprehensive digital pathology portfolio that already features the

best-in-class CE-marked 3DHistech P1000 WSI scanner*.

Aiforia aims to equip pathologists with AI-powered, secure, and scalable

cloud-based software for high precision image analysis that can be used in

preclinical research and clinical diagnostics. Their solutions aim to enhance

the speed and accuracy of pharmaceutical drug development and cancer

diagnostics using intuitive, AI-powered software. Aiforia's software currently

has over 3,000 pathologists and scientists as users in over 50 countries.

Aiforia recently announced the CE-IVD marking for its Clinical AI Model for

Breast Cancer: Ki67, a widely used key biomarker in breast cancer diagnostics,

as part of the company's upcoming Clinical Suites. The Aiforia Clinical Suites

are under development to support the diagnosis of some of the world's most

prevalent cancers such as breast, lung, prostate, and more. The Suites,

intended for release and regulatory filings over the coming years, are

portfolios of powerful tools enabling pathologists to harness the power of AI

to support them in accelerating sample review, enhancing diagnostic accuracy,

and ultimately in improving patient outcomes.

Aiforia's offering for preclinical assessment consists of bespoke AI model

development services backed by Aiforia's in-house science team using an

intuitive cloud-based platform, catering to a wide range of therapy areas. Over

400 AI models for preclinical research have already been developed using

Aiforia's solutions.

"This alliance with Aiforia to commercialize their highly innovative portfolio

of AI-based digital pathology solutions is another exciting step in building

our presence in this growing area of cancer diagnostics," explained John

Sweeney, President, Epredia. "We are pleased to be adding the Aiforia offering

to our portfolio of digital pathology solutions which now include cutting edge

AI software from the largest players in the field bundled with our portfolio of

best in class whole slide imaging scanners developed by 3DHistech. The product

development expertise of Aiforia that has gone into these solutions ideally

complements our global commercial reach and will enable us to bring their

solutions to more pathologists across the world."

"With their global presence in the pathology market and our expertise in

delivering AI-based solutions for pathologists, Epredia is the ideal commercial

partner to help us broaden the international reach of Aiforia's powerful AI

software to pathologists working in clinical diagnostics and preclinical drug

development," explained Jukka Tapaninen, Chief Executive Officer of Aiforia.

"Our mission is to become a global leader in AI-assisted image analysis to

improve the efficiencies of healthcare systems and enable better patient

outcomes."

* Regulatory requirements for the 3DHistech P1000 scanner and Aiforia's

pathology solutions vary by country, please consult with your commercial

partner to confirm the availability and approved use of the scanner and

Aiforia's pathology solutions in your country.

SOURCE:  Epredia